RU2012111235A - Комбинированная терапия композициями наночастиц таксана и ингибиторами хэджхог - Google Patents
Комбинированная терапия композициями наночастиц таксана и ингибиторами хэджхог Download PDFInfo
- Publication number
- RU2012111235A RU2012111235A RU2012111235/15A RU2012111235A RU2012111235A RU 2012111235 A RU2012111235 A RU 2012111235A RU 2012111235/15 A RU2012111235/15 A RU 2012111235/15A RU 2012111235 A RU2012111235 A RU 2012111235A RU 2012111235 A RU2012111235 A RU 2012111235A
- Authority
- RU
- Russia
- Prior art keywords
- cancer
- hedgehog inhibitor
- nanoparticles
- composition
- albumin
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract 16
- 239000000203 mixture Substances 0.000 title claims abstract 14
- 239000002105 nanoparticle Substances 0.000 title claims abstract 14
- 238000002648 combination therapy Methods 0.000 title 1
- 241000289669 Erinaceus europaeus Species 0.000 claims abstract 15
- 206010028980 Neoplasm Diseases 0.000 claims abstract 10
- 201000011510 cancer Diseases 0.000 claims abstract 10
- 102000009027 Albumins Human genes 0.000 claims abstract 8
- 108010088751 Albumins Proteins 0.000 claims abstract 8
- 229940123237 Taxane Drugs 0.000 claims abstract 8
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims abstract 8
- 206010004146 Basal cell carcinoma Diseases 0.000 claims abstract 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract 4
- 206010017758 gastric cancer Diseases 0.000 claims abstract 4
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims abstract 4
- 229960005277 gemcitabine Drugs 0.000 claims abstract 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims abstract 4
- 201000002528 pancreatic cancer Diseases 0.000 claims abstract 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims abstract 4
- 201000011549 stomach cancer Diseases 0.000 claims abstract 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims abstract 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims abstract 2
- 206010004593 Bile duct cancer Diseases 0.000 claims abstract 2
- 206010005003 Bladder cancer Diseases 0.000 claims abstract 2
- QASFUMOKHFSJGL-LAFRSMQTSA-N Cyclopamine Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H](CC2=C3C)[C@@H]1[C@@H]2CC[C@@]13O[C@@H]2C[C@H](C)CN[C@H]2[C@H]1C QASFUMOKHFSJGL-LAFRSMQTSA-N 0.000 claims abstract 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims abstract 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims abstract 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract 2
- 208000000172 Medulloblastoma Diseases 0.000 claims abstract 2
- 208000034578 Multiple myelomas Diseases 0.000 claims abstract 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims abstract 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims abstract 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims abstract 2
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract 2
- 229930012538 Paclitaxel Natural products 0.000 claims abstract 2
- HZLFFNCLTRVYJG-WWGOJCOQSA-N Patidegib Chemical compound C([C@@]1(CC(C)=C2C3)O[C@@H]4C[C@H](C)CN[C@H]4[C@H]1C)C[C@H]2[C@H]1[C@H]3[C@@]2(C)CC[C@@H](NS(C)(=O)=O)C[C@H]2CC1 HZLFFNCLTRVYJG-WWGOJCOQSA-N 0.000 claims abstract 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims abstract 2
- 206010060862 Prostate cancer Diseases 0.000 claims abstract 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims abstract 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims abstract 2
- QASFUMOKHFSJGL-UHFFFAOYSA-N cyclopamine Natural products C1C=C2CC(O)CCC2(C)C(CC2=C3C)C1C2CCC13OC2CC(C)CNC2C1C QASFUMOKHFSJGL-UHFFFAOYSA-N 0.000 claims abstract 2
- 229960003668 docetaxel Drugs 0.000 claims abstract 2
- 230000000694 effects Effects 0.000 claims abstract 2
- 201000004101 esophageal cancer Diseases 0.000 claims abstract 2
- 208000005017 glioblastoma Diseases 0.000 claims abstract 2
- 201000007270 liver cancer Diseases 0.000 claims abstract 2
- 208000014018 liver neoplasm Diseases 0.000 claims abstract 2
- 201000005202 lung cancer Diseases 0.000 claims abstract 2
- 208000020816 lung neoplasm Diseases 0.000 claims abstract 2
- KLRRGBHZCJLIEL-UHFFFAOYSA-N n-[2-methyl-5-(methylaminomethyl)phenyl]-4-[(4-phenylquinazolin-2-yl)amino]benzamide Chemical compound CNCC1=CC=C(C)C(NC(=O)C=2C=CC(NC=3N=C4C=CC=CC4=C(C=4C=CC=CC=4)N=3)=CC=2)=C1 KLRRGBHZCJLIEL-UHFFFAOYSA-N 0.000 claims abstract 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims abstract 2
- 230000002611 ovarian Effects 0.000 claims abstract 2
- 229960001592 paclitaxel Drugs 0.000 claims abstract 2
- 229960005569 saridegib Drugs 0.000 claims abstract 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims abstract 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims abstract 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims abstract 2
- 229960004449 vismodegib Drugs 0.000 claims abstract 2
- BPQMGSKTAYIVFO-UHFFFAOYSA-N vismodegib Chemical group ClC1=CC(S(=O)(=O)C)=CC=C1C(=O)NC1=CC=C(Cl)C(C=2N=CC=CC=2)=C1 BPQMGSKTAYIVFO-UHFFFAOYSA-N 0.000 claims abstract 2
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 239000008389 polyethoxylated castor oil Substances 0.000 claims 1
- 229960005325 sonidegib Drugs 0.000 claims 1
- VZZJRYRQSPEMTK-CALCHBBNSA-N sonidegib Chemical compound C1[C@@H](C)O[C@@H](C)CN1C(N=C1)=CC=C1NC(=O)C1=CC=CC(C=2C=CC(OC(F)(F)F)=CC=2)=C1C VZZJRYRQSPEMTK-CALCHBBNSA-N 0.000 claims 1
- 210000005229 liver cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Optics & Photonics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1. Способ лечения рака у индивидуума, включающий введение индивидууму:a) эффективного количества композиции, содержащей наночастицы, включающие таксан и альбумин, иb) эффективного количества ингибитора хэджхог.2. Способ по п.1, где указанный ингибитор хэджхог ингибирует активность Smoothened.3. Способ по п.1, где указанным ингибитором хэджхог является циклопамин или его производное.4. Способ по п.1, где указанный ингибитор хэджхог выбран из группы, включающей GDC-0449, XL139, IPI926, IPI609 и LDE225.5. Способ по п.1, также включающий введение эффективного количества гемцитабина.6. Способ по п.3, также включающий введение эффективного количества гемцитабина.7. Способ по п.1, где рак выбран из группы, включающей базальноклеточную карциному, медуллобластому, глиобластому, множественную миелому, хроническую миелогенную лейкемию (ХМЛ), острую миелогенную лейкемию, рак поджелудочной железы, рак легких (мелкоклеточный рак легких и немелкоклеточный рак легких), рак пищевода, рак желудка, билиарный рак, рак простаты, рак печени, печеночно-клеточный рак, желудочно-кишечный рак, рак желудка, рак яичников и мочевого пузыря.8. Способ по п.7, где раком является рак поджелудочной железы.9. Способ по п.7, где раком является базальноклеточная карцинома.10. Способ по п.1, где композицию, содержащую наночастицы, включающие таксан и альбумин, и ингибитор хэджхог вводят одновременно.11. Способ по п.1, где композицию, содержащую наночастицы, включающие таксан и альбумин, и ингибитор хэджхог вводят последовательно.12. Способ по любому из пп.1-11, где таксаном является паклитаксел.13. Способ по любому из пп.1-11, где таксаном является доцетаксел.14. Способ по любому из пп.1-11, где средн�
Claims (22)
1. Способ лечения рака у индивидуума, включающий введение индивидууму:
a) эффективного количества композиции, содержащей наночастицы, включающие таксан и альбумин, и
b) эффективного количества ингибитора хэджхог.
2. Способ по п.1, где указанный ингибитор хэджхог ингибирует активность Smoothened.
3. Способ по п.1, где указанным ингибитором хэджхог является циклопамин или его производное.
4. Способ по п.1, где указанный ингибитор хэджхог выбран из группы, включающей GDC-0449, XL139, IPI926, IPI609 и LDE225.
5. Способ по п.1, также включающий введение эффективного количества гемцитабина.
6. Способ по п.3, также включающий введение эффективного количества гемцитабина.
7. Способ по п.1, где рак выбран из группы, включающей базальноклеточную карциному, медуллобластому, глиобластому, множественную миелому, хроническую миелогенную лейкемию (ХМЛ), острую миелогенную лейкемию, рак поджелудочной железы, рак легких (мелкоклеточный рак легких и немелкоклеточный рак легких), рак пищевода, рак желудка, билиарный рак, рак простаты, рак печени, печеночно-клеточный рак, желудочно-кишечный рак, рак желудка, рак яичников и мочевого пузыря.
8. Способ по п.7, где раком является рак поджелудочной железы.
9. Способ по п.7, где раком является базальноклеточная карцинома.
10. Способ по п.1, где композицию, содержащую наночастицы, включающие таксан и альбумин, и ингибитор хэджхог вводят одновременно.
11. Способ по п.1, где композицию, содержащую наночастицы, включающие таксан и альбумин, и ингибитор хэджхог вводят последовательно.
12. Способ по любому из пп.1-11, где таксаном является паклитаксел.
13. Способ по любому из пп.1-11, где таксаном является доцетаксел.
14. Способ по любому из пп.1-11, где средний диаметр наночастиц в композиции составляет не более приблизительно 200 нм.
15. Способ по п.12, где средний диаметр наночастиц в композиции составляет не более приблизительно 200 нм.
16. Способ по любому из пп.1-11, где массовое отношение альбумина и таксана в композиции наночастиц составляет менее приблизительно 1:1 - 9:1.
17. Способ по п.15, где массовое отношение альбумина и таксана в композиции наночастиц составляет менее приблизительно 1:1 - 9:1.
18. Способ по любому из пп.1-11, где композиция наночастиц практически не содержит Кремофор.
19. Способ по любому из пп.1-11, где индивидуумом является человек.
20. Способ по любому из пп.1-11, где ингибитор хэджхог вводят перорально.
21. Способ по любому из пп.1-11, где ингибитор хэджхог вводят до введения композиции наночастиц.
22. Способ по любому из пп.1-11, где ингибитор хэджхог вводят после введения композиции наночастиц.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23681309P | 2009-08-25 | 2009-08-25 | |
| US61/236,813 | 2009-08-25 | ||
| PCT/US2010/046684 WO2011025838A1 (en) | 2009-08-25 | 2010-08-25 | Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2012111235A true RU2012111235A (ru) | 2013-10-10 |
| RU2561055C2 RU2561055C2 (ru) | 2015-08-20 |
Family
ID=43628371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012111235/15A RU2561055C2 (ru) | 2009-08-25 | 2010-08-25 | Комбинированная терапия композициями наночастиц таксана и ингибиторами хэджхог |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US20130045240A1 (ru) |
| EP (2) | EP3103452A1 (ru) |
| JP (1) | JP2013503174A (ru) |
| KR (1) | KR20120053052A (ru) |
| CN (1) | CN102573832B (ru) |
| AU (1) | AU2010286670B2 (ru) |
| BR (1) | BR112012004149A2 (ru) |
| CA (1) | CA2772301A1 (ru) |
| CR (1) | CR20120115A (ru) |
| DK (1) | DK2470173T3 (ru) |
| ES (1) | ES2577024T3 (ru) |
| HR (1) | HRP20160551T8 (ru) |
| HU (1) | HUE029094T2 (ru) |
| IL (1) | IL218316A (ru) |
| IN (1) | IN2012DN02018A (ru) |
| MX (1) | MX340670B (ru) |
| MY (1) | MY162514A (ru) |
| NI (1) | NI201200030A (ru) |
| NZ (1) | NZ598588A (ru) |
| PL (1) | PL2470173T3 (ru) |
| PT (1) | PT2470173E (ru) |
| RU (1) | RU2561055C2 (ru) |
| SG (2) | SG10201609290PA (ru) |
| UA (1) | UA110196C2 (ru) |
| WO (1) | WO2011025838A1 (ru) |
| ZA (1) | ZA201201531B (ru) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8853260B2 (en) * | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| ES2685436T3 (es) | 2002-12-09 | 2018-10-09 | Abraxis Bioscience, Llc | Composiciones y procedimientos para administración de agentes farmacológicos |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| NZ595313A (en) | 2005-02-18 | 2013-03-28 | Abraxis Bioscience Llc | The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases |
| SI3311805T1 (sl) * | 2005-08-31 | 2020-07-31 | Abraxis Bioscience, Llc | Sestave, ki zajemajo slabo vodotopne farmacevtske učinkovine in antimikrobna sredstva |
| EP3470071A1 (en) * | 2006-12-14 | 2019-04-17 | Abraxis BioScience, LLC | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| KR20150002886A (ko) * | 2007-03-07 | 2015-01-07 | 아브락시스 바이오사이언스, 엘엘씨 | 항암제로서 라파마이신 및 알부민을 포함하는 나노입자 |
| EP2155188B1 (en) * | 2007-06-01 | 2013-10-09 | Abraxis BioScience, LLC | Methods and compositions for treating recurrent cancer |
| EP3725775A1 (en) | 2009-02-17 | 2020-10-21 | Syntrix Biosystems, Inc. | Pyridine- and pyrimidinecarboxamides as cxcr2 modulators |
| JP5781500B2 (ja) | 2009-04-15 | 2015-09-24 | アブラクシス バイオサイエンス， エルエルシー | プリオンを含まないナノ粒子組成物および方法 |
| LT2552438T (lt) * | 2010-03-26 | 2016-09-26 | Abraxis Bioscience, Llc | Hepatoceliulinės karcinomos gydymo būdai |
| HUE030207T2 (en) | 2010-03-29 | 2017-04-28 | Abraxis Bioscience Llc | Cancer Treatment Procedures |
| JP6242213B2 (ja) | 2010-03-29 | 2017-12-06 | アブラクシス バイオサイエンス， エルエルシー | 薬物送達および治療用薬剤の有効性を向上させる方法 |
| US20130109672A1 (en) * | 2010-04-29 | 2013-05-02 | The United States Of America,As Represented By The Secretary, Department Of Health And Human Service | Activators of human pyruvate kinase |
| PH12012502378A1 (en) * | 2010-06-02 | 2013-02-11 | Abraxis Bioscience Llc | Methods of treating bladder cancer |
| RU2576609C2 (ru) * | 2010-06-04 | 2016-03-10 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечение рака поджелудочной железы |
| EP2575774A4 (en) * | 2010-06-07 | 2014-01-22 | Abraxis Bioscience Llc | COMBINATION THERAPY PROCEDURE FOR THE TREATMENT OF PROLIFERATIVE DISEASES |
| AU2011293612B2 (en) | 2010-08-23 | 2015-11-26 | Syntrix Biosystems Inc. | Aminopyridine- and aminopyrimidinecarboxamides as CXCR2 modulators |
| KR101970342B1 (ko) | 2011-04-28 | 2019-04-18 | 아브락시스 바이오사이언스, 엘엘씨 | 나노입자 조성물의 혈관내 전달 및 그의 용도 |
| WO2012151544A1 (en) | 2011-05-05 | 2012-11-08 | Wisconsin Alumni Research Foundation | Micelles for the solubilization of gossypol |
| LT2790675T (lt) | 2011-12-14 | 2019-11-11 | Abraxis Bioscience Llc | Polimerinių užpildų panaudojimas dalelių liofilizacijai arba šaldymui |
| US9248128B2 (en) | 2012-01-27 | 2016-02-02 | New York University | Method for enhancing remyelination using GLI1 inhibitors |
| CN103570625A (zh) | 2012-07-19 | 2014-02-12 | 南京英派药业有限公司 | N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用 |
| JP6385352B2 (ja) * | 2012-10-15 | 2018-09-05 | アジオス ファーマシューティカルズ， インコーポレイテッド | 治療化合物および組成物 |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| WO2014087413A1 (en) * | 2012-12-03 | 2014-06-12 | Vishwa Vidya Peetham University Amrita | Nanoparticles comprising sorafenib |
| US20140186447A1 (en) * | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
| US20140199405A1 (en) * | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| US10744110B2 (en) * | 2013-03-12 | 2020-08-18 | Abraxis Bioscience, Llc | Methods of treating lung cancer |
| NZ630213A (en) | 2013-03-14 | 2017-05-26 | Abraxis Bioscience Llc | Methods of treating bladder cancer |
| WO2014144747A1 (en) * | 2013-03-15 | 2014-09-18 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| US9045477B2 (en) | 2013-03-15 | 2015-06-02 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| WO2014179678A1 (en) * | 2013-05-03 | 2014-11-06 | Angiostrass Llc | Methods of treating cancer and angioproliferative disorders |
| KR102260403B1 (ko) * | 2013-06-05 | 2021-06-04 | 주식회사 씨앤드씨신약연구소 | 헤테로사이클 유도체 및 그의 용도 |
| WO2015002915A1 (en) | 2013-07-02 | 2015-01-08 | Bristol-Myers Squibb Company | Tricyclic pyri do-carboxam i d e derivatives as rock inhibitors |
| ES2634628T3 (es) | 2013-07-02 | 2017-09-28 | Bristol-Myers Squibb Company | Derivados tricíclicos de pirido-carboxamida como inhibidores ROCK |
| WO2015003360A2 (en) * | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| US10682415B2 (en) | 2013-07-22 | 2020-06-16 | Wisconsin Alumni Research Foundation | Thermogel formulation for combination drug delivery |
| US10046002B2 (en) | 2013-08-02 | 2018-08-14 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| US8969365B2 (en) | 2013-08-02 | 2015-03-03 | Syntrix Biosystems, Inc. | Thiopyrimidinecarboxamides as CXCR1/2 modulators |
| US10561676B2 (en) | 2013-08-02 | 2020-02-18 | Syntrix Biosystems Inc. | Method for treating cancer using dual antagonists of CXCR1 and CXCR2 |
| WO2015042108A1 (en) * | 2013-09-17 | 2015-03-26 | Genentech, Inc. | Methods of using anti-lgr5 antibodies |
| GB201416513D0 (en) * | 2014-09-18 | 2014-11-05 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| CN105085489B (zh) * | 2014-11-05 | 2019-03-01 | 益方生物科技（上海）有限公司 | 嘧啶或吡啶类化合物、其制备方法和医药用途 |
| KR20160066490A (ko) * | 2014-12-02 | 2016-06-10 | 주식회사 씨앤드씨신약연구소 | 헤테로사이클 유도체 및 그의 용도 |
| MX394452B (es) | 2015-02-27 | 2025-03-21 | Curtana Pharmaceuticals Inc | Inhibicion de la actividad de olig2. |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| EP3307725A1 (en) | 2015-06-11 | 2018-04-18 | Basilea Pharmaceutica International AG | Efflux-pump inhibitors and therapeutic uses thereof |
| KR102798594B1 (ko) | 2015-06-29 | 2025-04-18 | 아브락시스 바이오사이언스, 엘엘씨 | 상피양 세포 종양을 치료하는 방법 |
| CN106421786A (zh) * | 2015-08-06 | 2017-02-22 | 复旦大学 | Hedgehog通路抑制剂和纳米药物递送系统的药物组合物及其用途 |
| JP2018052878A (ja) * | 2016-09-29 | 2018-04-05 | 第一三共株式会社 | ピリジン化合物 |
| US10660909B2 (en) | 2016-11-17 | 2020-05-26 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| AU2019239953B2 (en) | 2018-03-20 | 2025-01-02 | Abraxis Bioscience, Llc | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
| MX2021014686A (es) * | 2019-05-29 | 2022-04-06 | Nelum Corp | Métodos y usos para tratar el cáncer. |
| CA3158764A1 (en) | 2019-10-28 | 2021-05-06 | Abraxis Bioscience, Llc | Pharmaceutical compositions of albumin and rapamycin |
| CN112755042A (zh) * | 2019-11-06 | 2021-05-07 | 绍兴维帆生物技术有限公司 | 一种抗肿瘤药物的联合使用治疗白血病的方法 |
| KR102526793B1 (ko) * | 2021-11-03 | 2023-04-28 | 주식회사 에스엔바이오사이언스 | 입도분포 유지 안정성이 개선된 알부민 결합 탁산 나노입자 제조방법 |
| WO2025120551A1 (ko) * | 2023-12-08 | 2025-06-12 | 제이더블유중외제약 주식회사 | 헤테로사이클 유도체 제조에 사용되는 중간체 화합물, 이의 제조 방법 및 이를 이용한 헤테로사이클 유도체의 제조 방법 |
| WO2025120550A1 (ko) * | 2023-12-08 | 2025-06-12 | 제이더블유중외제약 주식회사 | 헤테로사이클 유도체 제조에 사용되는 중간체 화합물, 이의 제조 방법 및 이를 이용한 헤테로사이클 유도체의 제조 방법 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US20070117863A1 (en) * | 1993-02-22 | 2007-05-24 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| KR100789008B1 (ko) * | 1997-06-27 | 2007-12-26 | 아브락시스 바이오사이언스 인크. | 신규 약물 제제 |
| EP1133519B1 (en) | 1998-11-02 | 2008-08-13 | Curis, Inc. | Functional antagonists of hedgehog activity |
| US6291516B1 (en) | 1999-01-13 | 2001-09-18 | Curis, Inc. | Regulators of the hedgehog pathway, compositions and uses related thereto |
| JP2002538167A (ja) | 1999-03-03 | 2002-11-12 | バイオジェン インコーポレイテッド | 脂質の代謝および貯蔵を調節する方法 |
| JP2003502292A (ja) | 1999-06-01 | 2003-01-21 | バイオジェン インコーポレイテッド | ヘッジホッグタンパク質のポリマー結合体及び利用 |
| US7708998B2 (en) | 2000-10-13 | 2010-05-04 | Curis, Inc. | Methods of inhibiting unwanted cell proliferation using hedgehog antagonists |
| US20050192262A1 (en) * | 2001-03-13 | 2005-09-01 | Tomas Hagstrom | Treatment of tumours |
| AU2002327390B2 (en) | 2001-07-27 | 2008-06-26 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| ITMI20020680A1 (it) * | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento |
| ATE404200T1 (de) | 2002-04-22 | 2008-08-15 | Univ Johns Hopkins Med | Modulatoren von hedgehog signalpfaden, zusammensetzungen und verwandte verwendungen |
| ES2685436T3 (es) | 2002-12-09 | 2018-10-09 | Abraxis Bioscience, Llc | Composiciones y procedimientos para administración de agentes farmacológicos |
| FR2850022B1 (fr) * | 2003-01-22 | 2006-09-08 | Centre Nat Rech Scient | Nouvelle utilisation de la mifepristone et de ses derives comme modulateurs de la voie de signalisation des proteines hedgehog et ses applications |
| PE20050206A1 (es) * | 2003-05-26 | 2005-03-26 | Schering Ag | Composicion farmaceutica que contiene un inhibidor de histona deacetilasa |
| WO2006039569A1 (en) * | 2004-09-30 | 2006-04-13 | The University Of Chicago | Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents |
| US7816369B2 (en) * | 2004-11-03 | 2010-10-19 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| NZ595313A (en) | 2005-02-18 | 2013-03-28 | Abraxis Bioscience Llc | The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases |
| JP5368093B2 (ja) | 2005-08-31 | 2013-12-18 | アブラクシス バイオサイエンス， エルエルシー | 増大した安定性を有する難水溶性薬剤の組成物および調製の方法 |
| EP1947936A4 (en) * | 2005-11-04 | 2010-02-10 | Merck & Co Inc | METHOD FOR THE USE OF SAHA AND BORTEZOMIB FOR THE TREATMENT OF CANCER |
| AR054215A1 (es) * | 2006-01-20 | 2007-06-13 | Eriochem Sa | Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit |
| EP1998785A4 (en) | 2006-02-21 | 2009-06-17 | Univ Michigan | TREATMENT OF CANCER BY AN ANTAGONIST OF THE HEDGEHOG SIGNALING PATH |
| DE102006038747A1 (de) | 2006-08-17 | 2008-03-20 | Khs Ag | Dichtanordnung für eine Drehlagervorrichtung |
| JP4897518B2 (ja) | 2007-03-02 | 2012-03-14 | 株式会社ニチベイ | ブラインドの操作装置 |
| EP2134695A4 (en) * | 2007-03-14 | 2011-05-25 | Exelixis Inc | HEMGE OF THE HEDGEHOG SIGNAL PATH |
| MY156814A (en) * | 2007-03-15 | 2016-03-31 | Novartis Ag | Organic compounds and their uses |
| EP2146707A2 (en) | 2007-05-03 | 2010-01-27 | Abraxis BioScience, LLC | Methods and compositions for treating pulmonary hypertension |
| JP5373777B2 (ja) * | 2007-06-07 | 2013-12-18 | アイアールエム・リミテッド・ライアビリティ・カンパニー | ヘッジホッグ経路モジュレーターとしてのビフェニルカルボキサミド誘導体 |
| US20090123932A1 (en) * | 2007-11-09 | 2009-05-14 | Anne-Marie Mes-Masson | Quantitative test to detect disease progression markers of epithelial ovarian cancer patients |
| WO2009086416A1 (en) | 2007-12-27 | 2009-07-09 | Infinity Pharmaceuticals, Inc. | Therapeutic cancer treatments |
| JP5715420B2 (ja) * | 2007-12-28 | 2015-05-07 | ジェネンテック， インコーポレイテッド | 抗ヘッジホッグ抗体 |
-
2010
- 2010-08-25 SG SG10201609290PA patent/SG10201609290PA/en unknown
- 2010-08-25 UA UAA201203446A patent/UA110196C2/ru unknown
- 2010-08-25 ES ES10812593.1T patent/ES2577024T3/es active Active
- 2010-08-25 KR KR1020127007526A patent/KR20120053052A/ko not_active Ceased
- 2010-08-25 NZ NZ598588A patent/NZ598588A/en not_active IP Right Cessation
- 2010-08-25 IN IN2018DEN2012 patent/IN2012DN02018A/en unknown
- 2010-08-25 RU RU2012111235/15A patent/RU2561055C2/ru active
- 2010-08-25 PT PT108125931T patent/PT2470173E/pt unknown
- 2010-08-25 PL PL10812593.1T patent/PL2470173T3/pl unknown
- 2010-08-25 US US13/392,501 patent/US20130045240A1/en not_active Abandoned
- 2010-08-25 EP EP16167017.9A patent/EP3103452A1/en not_active Withdrawn
- 2010-08-25 HR HRP20160551TT patent/HRP20160551T8/hr unknown
- 2010-08-25 MY MYPI2012000838A patent/MY162514A/en unknown
- 2010-08-25 JP JP2012526948A patent/JP2013503174A/ja active Pending
- 2010-08-25 AU AU2010286670A patent/AU2010286670B2/en active Active
- 2010-08-25 SG SG2012013157A patent/SG178873A1/en unknown
- 2010-08-25 CN CN201080045983.0A patent/CN102573832B/zh active Active
- 2010-08-25 EP EP10812593.1A patent/EP2470173B1/en active Active
- 2010-08-25 DK DK10812593.1T patent/DK2470173T3/en active
- 2010-08-25 MX MX2012002460A patent/MX340670B/es active IP Right Grant
- 2010-08-25 HU HUE10812593A patent/HUE029094T2/hu unknown
- 2010-08-25 CA CA2772301A patent/CA2772301A1/en not_active Abandoned
- 2010-08-25 BR BR112012004149A patent/BR112012004149A2/pt not_active Application Discontinuation
- 2010-08-25 WO PCT/US2010/046684 patent/WO2011025838A1/en active Application Filing
-
2012
- 2012-02-24 NI NI201200030A patent/NI201200030A/es unknown
- 2012-02-26 IL IL218316A patent/IL218316A/en active IP Right Grant
- 2012-02-29 ZA ZA2012/01531A patent/ZA201201531B/en unknown
- 2012-03-12 CR CR20120115A patent/CR20120115A/es unknown
-
2013
- 2013-02-28 US US13/781,487 patent/US20140072630A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012111235A (ru) | Комбинированная терапия композициями наночастиц таксана и ингибиторами хэджхог | |
| JP2013503174A5 (ru) | ||
| Zhou et al. | Artesunate induces autophagy dependent apoptosis through upregulating ROS and activating AMPK-mTOR-ULK1 axis in human bladder cancer cells | |
| Roy et al. | Lycorine: A prospective natural lead for anticancer drug discovery | |
| NZ593343A (en) | Combination cancer treatment conprising Abraxane and an inflamatory inhibitor | |
| HRP20160609T1 (hr) | Postupci liječenja hepatocelularnog karcinoma | |
| PH12012500504A1 (en) | N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine in the treatment of antimitotic agent resistent cancer | |
| RS20080167A (en) | Novel improved compositions for cancer therapy | |
| RU2010153576A (ru) | Противоопухолевые эффекты комбинаций каннабиноидных соединений | |
| PE20090156A1 (es) | Nuevas pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas | |
| WO2008081927A1 (ja) | 抗癌剤の併用による癌治療方法 | |
| JP2010523696A5 (ru) | ||
| NZ708506A (en) | Methods of treating bladder cancer | |
| JP2012506448A5 (ru) | ||
| NZ588913A (en) | Liver cancer drug | |
| TR201905480T4 (tr) | Paklitaksel, paklitaksel analogları veya paklitaksel konjugatlarının farmasötik bileşimleri ve ilgili preparasyon ve kullanım yöntemleri. | |
| AR086652A1 (es) | Metodos de tratamiento, composiciones farmaceuticas y usos de los mismos | |
| RU2012110580A (ru) | Способы скрининга in vivo | |
| ME01881B (me) | Topijske formulacije koenzima q10 i postupci upotrebe | |
| ME00937B (me) | Kombinovane terapije koje sadrže hinoksalinske inhibitore pi3k-alfa za upotrebu u liječenju kancera | |
| RU2010140890A (ru) | Улучшенные способы противоопухолевого лечения | |
| JP2019521180A5 (ru) | ||
| WO2010135534A3 (en) | Compositions for the treatment of metastatic cancer and methods of use thereof | |
| UA107691C2 (ru) | Противораковая комбинация лекарственного средства на основе артемизинина с другими химиотерапевтическими средствами | |
| Zhou et al. | Discovery and optimization of withangulatin A derivatives as novel glutaminase 1 inhibitors for the treatment of triple-negative breast cancer |